NCT07641361 Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
| NCT ID | NCT07641361 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Obesity & Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-15 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-06-15 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-60 * Recently prescribed a GLP-1RA (within one week of prescription) * Fluent in English * Willing to complete the study protocol Exclusion Criteria: * Children and adults \> 60 years of age * Those not taking a GLP-1RA * Those who have been on a GLP-1RA longer than one week * Not fluent in English * Those who are pregnant or planning on becoming pregnant during the duration of the study * Unwilling to comply with study protocol * People with cardiac implants
Contact & Investigator
Katherine N Balantekin, PhD, RD
PRINCIPAL INVESTIGATOR
University at Buffalo
Frequently Asked Questions
Who can join the NCT07641361 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Obesity & Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07641361 currently recruiting?
Yes, NCT07641361 is actively recruiting participants. Visit ClinicalTrials.gov or contact State University of New York at Buffalo to inquire about joining.
Where is the NCT07641361 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT07641361 clinical trial?
NCT07641361 is sponsored by State University of New York at Buffalo. The principal investigator is Katherine N Balantekin, PhD, RD at University at Buffalo. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.